AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteAlvimopan behaves as a peripherally acting ??-opioid antagonist. Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract.
More Information Supplier PageAlvimopan behaves as a peripherally acting ??-opioid antagonist. Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract.
More Information Supplier PageAlvimopan behaves as a peripherally acting ??-opioid antagonist. Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract.
More Information Supplier PageAlvimopan behaves as a peripherally acting ??-opioid antagonist. Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract.
More Information Supplier PageAlvimopan dihydrate(LY 246736, ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAlvimopan dihydrate(LY 246736, ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAlvimopan dihydrate(LY 246736, ADL 8-2698) is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAlvimopan monohydrate is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAlvimopan monohydrate is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAlvimopan monohydrate is a peripherally acting mu-opioid receptor (PAM-OR, IC50= 1.7 nM) antagonist for accelerating gastrointestinal recovery after surgery.
More Information Supplier PageAM 114, a derivative of boronic chalcone, is a potent small-molecule inhibitor of the proteasome that inhibits the chymotrypsin-like activity of the 20S proteasome, with a value of 50% inhibition concentration IC50 of approximately 1 uM, resulting in a significant accumulation of ubiquitinated p53 and other cellular proteins in whole cells without significantly disrupting the […]
More Information Supplier PageAM 114, a derivative of boronic chalcone, is a potent small-molecule inhibitor of the proteasome that inhibits the chymotrypsin-like activity of the 20S proteasome, with a value of 50% inhibition concentration IC50 of approximately 1 uM, resulting in a significant accumulation of ubiquitinated p53 and other cellular proteins in whole cells without significantly disrupting the […]
More Information Supplier PageAM 114, a derivative of boronic chalcone, is a potent small-molecule inhibitor of the proteasome that inhibits the chymotrypsin-like activity of the 20S proteasome, with a value of 50% inhibition concentration IC50 of approximately 1 uM, resulting in a significant accumulation of ubiquitinated p53 and other cellular proteins in whole cells without significantly disrupting the […]
More Information Supplier PageAM1220 is a potent synthetic cannabinoid (CB) with preference for the central CB1 receptor (Ki = 3.88 nM) over the CB2 receptor (Ki = 73.4 nM).
More Information Supplier PageAM1220 is a potent synthetic cannabinoid (CB) with preference for the central CB1 receptor (Ki = 3.88 nM) over the CB2 receptor (Ki = 73.4 nM).
More Information Supplier PageAM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively
More Information Supplier PageAM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively
More Information Supplier PageAM2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively
More Information Supplier PageAM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).
More Information Supplier PageAM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).
More Information Supplier PageAM2233 is a full agonist of the central cannabinoid (CB1) receptor (Ki = 2.8 nM).
More Information Supplier PageAM 580 is an analog of retinoic acid that acts as a selective RAR?? agonist.
More Information Supplier PageAM 580 is an analog of retinoic acid that acts as a selective RAR?? agonist.
More Information Supplier PageAM 580 is an analog of retinoic acid that acts as a selective RAR?? agonist.
More Information Supplier PageAM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.1 The physiological actions and metabolism of AM694 have not been characterized.
More Information Supplier PageAM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.1 The physiological actions and metabolism of AM694 have not been characterized.
More Information Supplier PageAM694 is a potent synthetic cannabinoid (CB) with Ki values of 0.08 and 1.44 nM for the CB1 and CB2 receptors, respectively.1 The physiological actions and metabolism of AM694 have not been characterized.
More Information Supplier PageAM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ??M for mouse or recombinant human LPA1, respectively
More Information Supplier PageAM095 is a potent LPA1 receptor antagonist because it inhibited GTP??S binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 ??M, respectively, and exhibited no LPA1 agonism.
More Information Supplier PageAM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ??M for mouse or recombinant human LPA1, respectively
More Information Supplier PageAM095 is a potent LPA1 receptor antagonist because it inhibited GTP??S binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 ??M, respectively, and exhibited no LPA1 agonism.
More Information Supplier PageAM095 is a novel, potent and orally bioavailable antagonist of lysophosphatidic acid type 1 receptor (LPA1) with IC50 values of 0.73 and 0.98 ??M for mouse or recombinant human LPA1, respectively
More Information Supplier PageAM095 is a potent LPA1 receptor antagonist because it inhibited GTP??S binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 ??M, respectively, and exhibited no LPA1 agonism.
More Information Supplier PageAM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
More Information Supplier PageAM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
More Information Supplier PageAM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
More Information Supplier PageAM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
More Information Supplier PageAM251 is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that displays 306-fold selectivity over CB2 receptors.
More Information Supplier PageAM630 is a selectivity CB2 antagonist with Ki of 31.2 nM, > 150 fold selectivity over CB1 receptor.
More Information Supplier PageAM630 is a selectivity CB2 antagonist with Ki of 31.2 nM, > 150 fold selectivity over CB1 receptor.
More Information Supplier PageAM630 is a selectivity CB2 antagonist with Ki of 31.2 nM, > 150 fold selectivity over CB1 receptor.
More Information Supplier PageAM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively.
More Information Supplier PageAM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively.
More Information Supplier PageAM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively.
More Information Supplier PageAM966 is a high affinity, selective, oral antagonist of LPA1 receptor (lysophosphatidic acid receptor) with an IC50 value of 17 nM.
More Information Supplier PageAM966 is a high affinity, selective, oral antagonist of LPA1 receptor (lysophosphatidic acid receptor) with an IC50 value of 17 nM.
More Information Supplier PageAM966 is a high affinity, selective, oral antagonist of LPA1 receptor (lysophosphatidic acid receptor) with an IC50 value of 17 nM.
More Information Supplier PageAmadacycline is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.
More Information Supplier PageAmadacycline is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.
More Information Supplier PageAmadacycline is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.
More Information Supplier Page
